TITLE

Sickle Cell Trait Is Associated with a Delayed Onset of Malaria: Implications for Time-to-Event Analysis in Clinical Studies of Malaria

AUTHOR(S)
Crompton, Peter D.; Traore, Boubacar; Kayentao, Kassoum; Doumbo, Safiatou; Ongoiba, Aissata; Diakite, Seidina A. S.; Krause, Michael A.; Doumtabe, Didier; Kone, Younoussou; Weiss, Greta; Chiung-Yu Huang; Doumbia, Seydou; Guindo, Aldiouma; Fairhurst, Rick M.; Miller, Louis H.; Pierce, Susan K.; Doumbo, Ogobara K.
PUB. DATE
November 2008
SOURCE
Journal of Infectious Diseases;11/1/2008, Vol. 198 Issue 9, p1265
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background. The World Health Organization (WHO) recently recommended that the time to first malaria episode serve as the primary end point in phase III malaria vaccine trials-the first of which will be held in Africa. Although common red blood cell (RBC) polymorphisms such as sickle hemoglobin (HbS) are known to protect against malaria in Africa, their impact on this end point has not been investigated. Methods. A longitudinal study of 225 individuals aged 2-25 years was conducted in Mali. The association between common RBC polymorphisms and the time to first malaria episode was evaluated. Results. Among children aged 2-10 years, sickle cell trait (HbAS) was associated with a 34-day delay in the median time to first malaria episode (P = .017). Cox regression analysis showed that greater age (hazard ratio [HR], 0.87 [95% CI, 0.80-0.94]; P = .001), HbAS (HR, 0.48 [95% CI, 0.26-0.91]; P = .024), and asymptomatic parasitemia at enrollment (HR, 0.35 [95% CI, 0.14-0.85]; P = .021) were associated with decreased malaria risk. Conclusion. Given the delay in the time to first malaria episode associated with HbAS, it would be advisable for clinical trials and observational studies that use this end point to include Hb typing in the design of studies conducted in areas where HbAS is prevalent.
ACCESSION #
35134363

 

Related Articles

  • Differential Induction of Functional IgG Using the Plasmodium falciparum Placental Malaria Vaccine Candidate VAR2CSA. Pinto, Vera V.; Ditlev, Sisse B.; Jensen, Kamilla E.; Resende, Mafalda; Dahlbäck, Madeleine; Andersen, Gorm; Andersen, Pernille; Theander, Thor G.; Salanti, Ali; Nielsen, Morten A. // PLoS ONE;2011, Vol. 6 Issue 3, p1 

    Background: In Plasmodium falciparum malaria endemic areas placental malaria (PM) is an important complication of malaria. The recurrence of malaria in primigravidae women irrespective of acquired protection during childhood is caused by the interaction between the parasite-expressed VAR2CSA...

  • Pseudoeosinophilia associated with malaria infection determined in the Sysmex XE-2100 hematology analyzer. Jungwon Huh; Junseop Jung; Hyungdu Yoon; Whasoon Chung // Annals of Hematology;Jun2005, Vol. 84 Issue 6, p400 

    Hemozoin is known to be an end product of hemoglobin digestion by the malaria parasite. Hemozoin is a birefringent crystal, and thus hemozoin-containing white blood cells (WBCs) may show the atypical light scattering pattern. The purpose of this study was to investigate pseudoeosinophilia...

  • Medicine: Knockout malaria vaccine? Ménard, Robert // Nature;1/13/2005, Vol. 433 Issue 7022, p113 

    Focuses on the elusiveness of an effective vaccine against malaria. Search for a genetically manipulated malaria parasite; Appeal to the idea of vaccines involving live attenuated parasites.

  • A Malaria Vaccine Based on the Polymorphic Block 2 Region of MSP-1 that Elicits a Broad Serotype-Spanning Immune Response. Cowan, Graeme J. M.; Creasey, Alison M.; Dhanasarnsombut, Kelwalin; Thomas, Alan W.; Remarque, Edmond J.; Cavanagh, David R. // PLoS ONE;2011, Vol. 6 Issue 10, p1 

    Polymorphic parasite antigens are known targets of protective immunity to malaria, but this antigenic variation poses challenges to vaccine development. A synthetic MSP-1 Block 2 construct, based on all polymorphic variants found in natural Plasmodium falciparum isolates has been designed,...

  • A high cell density fermentation strategy to produce recombinant malarial antigen inE. coli. Yazdani, Syed; Shakri, Ahmad; Chitnis, Chetan // Biotechnology Letters;Dec2004, Vol. 26 Issue 24, p1891 

    A high cell density cultivation method was developed to produce recombinant PvRII, a malaria vaccine candidate, inE. colifor use in vaccine studies. Cells were grown in completely defined media and glucose was fed to achieve a specific growth rate of 0.12 h-1 until cells reached 55 g dry wt l-1....

  • Clinical Case Definitions and Malaria Vaccine Efficacy. Rogers, William O.; Atuguba, Frank; Oduro, Abraham R.; Hodgson, Abraham; Koram, Kwadwo A. // Journal of Infectious Diseases;2/1/2006, Vol. 193 Issue 3, p467 

    Reported efficacies from vaccine trials may depend heavily on the clinical case definition used in the trial. The dependence may be particularly striking for diseases such as malaria, in which no single case definition is appropriate. We used logistic regression modeling of the relationship...

  • RESEARCH & TECHNOLOGY.  // MondayMorning;1/13/2014, Vol. 22 Issue 1, p6 

    The article presents a research by researcher Dmitri O. Lapotko from Rice University and colleagues, who have developed a rapid malaria test that uses a laser pulse, eliminating the need to draw blood. The malaria parasites feeding inside blood cells has minute amounts of hemozoin, iron crystals...

  • VAR2CSA Expression on the Surface of Placenta-Derived Plasmodium falciparum-Infected Erythrocytes. Magistrado, Pamela; Salanti, Ali; Tuikue Ndam, Nicaise G.; Mwakalinga, Steven B.; Resende, Mafalda; Dahlbäck, Madeleine; Hviid, Lars; Lusingu, John; Theander, Thor G.; Nielsen, Morten A. // Journal of Infectious Diseases;10/1/2008, Vol. 198 Issue 7, p1071 

    Malaria remains a major threat, in sub-Saharan Africa primarily, and the most deadly infections are those with Plasmodium falciparum. Pregnancy-associated malaria is a clinically important complication of infection; it results from a unique interaction between proteoglycans in the placental...

  • Bring on the X prize for vaccines.  // New Scientist;10/23/2004, Vol. 184 Issue 2470, p3 

    The article reports that finally an experimental vaccine seems to protect children against the worst ravages of malaria. Yet this raises the urgent question of what happens next: who pays for large clinical trials and building the production plant? Vaccine companies pay for trials and gear up...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics